Ϫ in pulmonary artery (PA) rings isolated from normal rats and those exposed to hypoxia for 3 days. Lack of extracellular HCO 3 Ϫ in normal PA rings significantly attenuated endothelial O 2 Ϫ ⅐ release, opposed hypoxic vasoconstriction, and enhanced acetylcholine-mediated vasodilation. Release of O 2 Ϫ ⅐ was also inhibited by an AE2 inhibitor (SITS) and abolished in normoxia by an NO synthase inhibitor (N G -nitro-L-arginine methyl ester). In contrast, hypoxia increased PA AE2 protein expression and O 2 Ϫ ⅐ release; the latter was not affected by N G -nitro-L-arginine methyl ester or other inhibitors of enzymatic O 2 Ϫ ⅐ generation. Enhanced O 2 Ϫ ⅐ release by uncoupling NO synthase with geldanamycin was attenuated by hypoxia or by HCO 3 Ϫ elimination. These results indicate that O 2 Ϫ ⅐ produced by endothelial NOS in normoxia and unidentified sources in hypoxia regulate pulmonary vascular tone via AE2.
anion exchange protein; nitric oxide; endothelial nitric oxide synthase; hypoxia THE PULMONARY CIRCULATION accommodates the entire cardiac output but is maintained at a substantially lower vascular resistance than the systemic vasculature. In addition, pulmonary arteries respond to regional hypoxia with vasoconstriction, which helps maintain ventilation-perfusion (V A /Q) matching. The biochemical mechanisms that regulate vascular tone at physiological O 2 concentrations are complex and incompletely understood but involve potassium channel activity, cytochrome P-450, and changes in free intracellular calcium concentration, as well as release of vasoactive mediators, including reactive nitrogen species and reactive oxygen species (ROS) (3, 13, 28, 43) .
The endothelium-derived relaxing factor NO⅐, generated from L-arginine by nitric oxide (NO) synthase (NOS) activity, contributes to basal vascular tone in normoxia and counteracts hypoxic pulmonary vasoconstriction (HPV) (28, 44) . Superoxide (O 2 Ϫ ⅐), a short-lived ROS formed by the univalent reduction of molecular O 2 , also influences vascular tone. O 2 Ϫ ⅐ causes vasoconstriction in part by reacting rapidly with NO⅐, which generates peroxynitrite (OONO Ϫ ) and inactivates NO⅐ as a functional endothelium-derived relaxing factor (6, 13, 21) . Vasoconstriction in severe hypoxia is partially mediated by decreased NOS activity, and decreased NO bioavailability may be exacerbated by increased production of O 2 Ϫ ⅐ in hypoxia (12, 20, 37, 44) . O 2 Ϫ ⅐ is particularly important in the extracellular compartment and vascular tissues of the lung where a specialized extracellular antioxidant enzyme, extracellular superoxide dismutase (EC-SOD) that inactivates extracellular O 2 Ϫ ⅐, is abundant. EC-SOD contributes to low pulmonary vascular tone under physiological conditions by scavenging extracellular O 2 Ϫ ⅐ and increasing NO bioactivity (31) .
Because O 2 Ϫ ⅐ is an anion, it does not readily cross cell membranes, and transport systems are required for it to leave the cell. For example, O 2 Ϫ ⅐ produced within erythrocyte membrane vesicles reduces cytochrome c in the extracellular medium. The appearance of O 2 Ϫ ⅐ in the extracellular milieu could be inhibited by 4,4Ј-diisothiocyanostilbene 2,2Ј-disulfonic acid (DIDS), a potent and relatively specific inhibitor of Cl Ϫ /HCO 3 Ϫ exchanger proteins (anion exchange proteins or AE). Therefore, O 2 Ϫ ⅐ transport through this anion channel was proposed (23) .
AE proteins are found in many tissues where they function as Cl Ϫ /HCO 3 Ϫ exchangers (1, 18) . AE1 is found in erythrocytes, and three tissue isoforms have been characterized (1, 18, 38) . In the lung, AE2 is the predominant isoform (8, 19, 27, 30, 42) , and inhibition of HCO 3 Ϫ -dependent AE activity blocks release of extracellular O 2 Ϫ ⅐ in the lung (30) . In this study, we tested the hypothesis that HCO 3 Ϫ -dependent release of O 2 Ϫ ⅐ contributes to the NO⅐-mediated regulation of pulmonary vascular tone. We performed experiments in the rat to examine the role of HCO 3 Ϫ -dependent O 2 Ϫ ⅐ release on NO⅐-mediated pulmonary vasodilation and hypoxic vasoconstriction in pulmonary artery (PA) rings and correlated the expression of AE2 in PAs of rats exposed to hypoxia with increases in O 2 Ϫ ⅐ release and decreased NO-mediated vasodilation. We report the novel finding that HCO 3 Ϫ -dependent release of O 2 Ϫ ⅐ by AE2 opposes NO-mediated pulmonary vasodilation under normoxic and hypoxic conditions.
MATERIALS AND METHODS

Animal exposures and isolation of PA segments and rings.
Adult male Sprague-Dawley rats were used for all studies. The Duke University IACAUC approved the experimental protocol. Control animals were kept in temperature-and light-controlled cages at sea level and fed standard laboratory chow ad libitum. Hypoxic animals were exposed for up to 7 days to hypobaric hypoxia at 17,000 ft (395 Torr), which produces arterial PO 2 values of 38-48 Torr (5) .
Isolated PA segments weighing 7-15 mg were obtained after the chests of anesthetized rats were opened and exsanguination of the animals. The left and right arteries were dissected quickly from the main PA and placed in physiological buffer (see buffers below). Rings (ϳ2 mm width) were obtained from first branch PAs for use in PA ring bioassays.
Composition of buffers. HCO 3 Ϫ -containing Krebs buffer (K-B) contained (in mM) 82.8 NaCl, 4.7 KCl, 2.4 KH2PO4, 1.2 MgSO4, 2.7 CaCl2, 11.1 dextrose, and 25 NaHCO3 at pH 7.4. HCO 3 Ϫ -free Krebs buffer (K-H) replaced NaHCO3 with 6 mM NaHEPES. NaCl was increased to 107 mM to maintain osmolarity, and pH was adjusted to 7.4 before use.
Detection of extracellular O 2 Ϫ ⅐. Two methods were used to detect extracellular O 2 Ϫ ⅐ in isolated rat lungs and PA segments: 1) reduction of nitroblue tetrazolium (NBT) in perfused lungs, and 2) SOD-inhibitable reduction of cytochrome c (Cyt c), which is highly specific for O 2 Ϫ ⅐ in isolated PA segments (2, 30) . Isolated rat lungs were inflated with air and perfused at 10 ml/min with 60 ml HCO 3 Ϫ -containing or HCO 3 Ϫ -free K-B with NBT (5 mg, n ϭ 2) at room temperature. NBT, a large divalent cation that does not cross cell membranes, detected the vascular O 2 Ϫ ⅐ appearance by a strong blue color developing in the lungs over 30 min. The lungs were inflation fixed at 20 mmHg with 4% paraformaldehyde, and lobes were photographed.
The PA segments were incubated in 2.4 ml buffer containing 50 M Cyt c, a concentration that remained stable in the buffer because it does not enter the cell in significant amounts. Samples of 400 l were removed at 5, 10, 15, and 20 min for differential spectrophotometry. Reduction of Cyt c was expressed per 10 mg wet weight of tissue as the change in absorbance at 550-540 nm relative to buffer-containing reference solution [50 M, Cyt c (ϳ90% oxidized)]. The 550-nm wavelength measures the peak of the reduced Cyt c heme, whereas the 540-nm wavelength does not change between reduced and oxidized forms and serves as a reference for light scattering. This method was chosen because it is one of the few that reliably detects extracellular superoxide release almost exclusively. SOD inhibition was determined by using Cu,Zn SOD (500 units, Sigma Chemical). Reduction and oxidation of Cyt c were tested under a wide range of experimental conditions in vessels of control rats and rats exposed to 3 days of hypobaric hypoxia (n ϭ 4-6 per group).
Control experiments were performed with all experimental agents in vitro to exclude independent effects on Cyt c reduction. The AE2 inhibitor DIDS interfered with the Cyt c assay in vitro, most likely because its strong yellow color interfered with the optical readings. Therefore, Cyt c reduction was measured in the presence of another stilbene AE2 inhibitor SITS, which demonstrated much less interference with the Cyt c signal. All studies involving Cyt c were conducted at the same PO 2 (ϳ150 mmHg).
PA ring bioassay. Rat PA rings were mounted in 15-ml tissue baths filled with HCO 3 Ϫ -containing K-B buffer and bubbled with 21% O 2-5% CO2-balance N2 at 37°C. Isometric tension was measured. All rings were suspended at similar baseline levels of tension (ϳ1 g). Tissue baths were thoroughly rinsed with fresh buffer between interventions. In all rings, a dose-response curve to phenylephrine (PE) was performed to test vascular responsiveness (10 Ϫ8 -10 Ϫ6 M) followed by acetylcholine (ACh) (10 Ϫ6 M) to confirm endothelial integrity.
NO-mediated vasodilation was tested with a dose response to ACh (10 Ϫ8 -10 Ϫ6 M) in rings maximally preconstricted with PE (10 Ϫ6 M). The response to ACh was compared in rings bathed in HCO 3 Ϫ -containing K-B buffer or HCO 3 Ϫ -free K-H buffer and expressed as the percentage of maximal ring tension with 10 Ϫ6 M PE for each ring. The response to ACh was also measured in the rings of animals exposed to hypobaric hypoxia for 3 days as outlined below. The 3-day time point was based on data demonstrating consistent increases in pulmonary vascular AE2 expression and minimal pulmonary vascular remodeling.
Acute HPV was produced in rings preconstricted with PE at half-maximal constriction based on the initial dose-response curve. The selected PE dose was between 10 Ϫ8 and 5 ϫ 10 Ϫ8 M in each experiment. Hypoxia was created by changing the gas mixture bubbled into the bath to 5% CO2-balance N2. The surface of the chamber was covered tightly with a plastic sheet (Parafilm) to minimize exposure to room air, and a second source of anoxic gas mixture was delivered to the air space above the buffer. Buffer samples (5 ml) collected after 30 min in gas-tight glass syringes were measured on a calibrated blood gas analyzer (IL model 1640) to ensure hypoxic conditions (PO2 20-25 mmHg). Rings exhibiting the well-described triphasic response to hypoxia were tested (4, 35) . The response to hypoxia in individual rings was repeated with both HCO 3 Ϫ -containing K-B buffer and HCO 3 Ϫ -free K-H buffer with half of the rings tested initially with each buffer. The data were expressed as the change in ring tension in grams from the baseline preconstricted tension for the initial constriction within seconds (phase I), subsequent vasodilation toward baseline tension (phase II), and late constriction 25 min after initiation of hypoxia (phase III).
Western analysis, RT-PCR, and immunohistochemistry (IHC).
For Western blot analysis, lung tissue was homogenized in 3% Nonidet-40, 150 mM NaCl, 1 mM MgCl2, 5 mM EDTA, and 50 mM Tris (pH 7.6). Lysis buffer included protease inhibitors (at 1:20): 2 mM 1,10 phenanthroline, 2 mM 3,4 diisocoumarin, and 0.4 mM E-64. Protein samples were separated by electrophoresis on a 7.5% polyacrylamide gel and transferred to a polyvinylidene fluoride membrane (Millipore). Membranes were probed with a primary polyclonal AE2 peptide antibody (1:1,000) and secondary goat anti-mouse antibody conjugated to horseradish peroxidase with detection by enhanced chemiluminescence (Amersham Pharmacia Biotech). Total RNA was isolated using a TRIzol kit, and RT-PCR was conducted on the rat lung and PA in control and exhypoxic conditions using gene-specific primers for AE2 and GAPDH based on the GenBank DNA database.
Optical densities for AE2 mRNA bands were normalized against those of the GAPDH bands. Rat AE2 primers were the following: AE2 sense 5Ј-TGTAGCAGCAACCACCTG-GAGT-3Ј and AE2 Antisense 5Ј-GCAGGAAGAAGGCGAT-GAAGAA-3Ј (39) . For immunohistochemistry, lungs were inflation fixed with 4% paraformaldehyde at 20 cmH2O pressure and paraffin embedded. Tissue sections were blocked with normal goat serum in 1% bovine albumin in PBS. Sections were then incubated with the primary polyclonal AE2 antibody (1:100 in 1% BSA/PBS) overnight at 4°C followed by a biotinylated goat anti-mouse IgG antibody (1: 1,000) and labeled with horseradish peroxidase-conjugated streptavadin (Innogenex). Slides were developed with 3,3Ј-diaminobenzidine and counterstained with hematoxylin. Negative controls were performed with normal mouse serum and antibody coincubated with AE2 peptide. Tissue sections were examined by light microscopy and photographed at ϫ132.
The primary AE2 antibody was developed in mouse ascites fluid against the rat AE2 COOH-terminal amino acids 1224-1237 (CEGVDEYNEMPMPV-COOH) (29, 47) . Peptide sequences were synthesized, purified, and confirmed by HPLC (Bio Synthesis). The AE2 antibody was affinity purified over a protein S sepharose column and characterized using immunoprecipitated AE2 protein Protein G IP kit (K&L Labs, Gaithersburg, MD) to confirm the identity of the single 95-kDa band and peptide competition (1:10) to inhibit the signal.
Statistical analysis. Grouped data are expressed as means Ϯ SE as indicated. Comparisons were made by analysis of variance followed by Fisher's least-square protected difference test using Statview software (SAS Institute; Cary, NC). P values are provided where statistical tests were performed.
RESULTS
In intact rat lungs and isolated PA rings and segments, the presence of HCO 3 Ϫ in the buffer was required for the extracellular release of O 2 Ϫ ⅐. The extracellular O 2 Ϫ ⅐ reduced NBT, indicated by a strong visible blue color in lungs infused with HCO 3 Ϫ -containing K-B buffer (Fig. 1A, left) . In contrast, when lungs were infused with HCO 3 Ϫ -free K-H buffer, NBT was not reduced, indicating that extracellular O 2 Ϫ ⅐ was not present (Fig. 1A, right) . Similarly, O 2 Ϫ ⅐ release from PA segments in K-B buffer, measured by SOD-inhibited reduction of Cyt c (50 M), increased over time. In K-H buffer, a small amount of reduced Cyt c originally present in the mixture was oxidized, shown by the negative signal (n ϭ 18) (Fig. 1B) . Oxidant release by PA segments in K-H buffer was found to involve H 2 O 2 because oxidation of Cyt c was eliminated by active but not inactive catalase (500 units) (n ϭ 4, P Ͻ 0.05) (Fig.  1B) .
In the PA ring bioassay, the presence of HCO 3 Ϫ strongly influenced the responses to both NO⅐-mediated pulmonary vasodilation by ACh and acute HPV. The dose-response curve to ACh (10 Ϫ8 -10 Ϫ5 M) produced a characteristic decrease in ring tension in K-B buffer expressed as percent maximum constriction. This is well characterized as NO dependent. The decrease in ring tension with ACh was significantly pronounced when isoosmotic HCO 3 Ϫ -free K-H buffer (pH 7.3) was substituted for HCO 3 Ϫ -containing buffer (K-B) (n ϭ 4-6, P Ͻ 0.05) ( Fig. 2A) , suggesting that HCO 3 Ϫ -dependent O 2 Ϫ ⅐ release is opposing NO bioactivity. Conversely, with acute hypoxia (5% CO 2 -balance N 2 ), initial and late vasoconstriction (phase I and III) were greatly attenuated HCO 3 Ϫ -free K-H buffer (n ϭ 3, P Ͻ 0.05) (Fig. 2B) , whereas vasodilation in phase II was not affected. A representative tracing (Fig. 2C) Ϫ ⅐ release from pulmonary vessels more specifically, reduction of Cyt c was analyzed in rings pretreated with SITS, a specific AE inhibitor. SITS (100 M) abolished reduction of Cyt c by vessels in K-B buffer (Fig. 3A) . The requirement for intact vascular endothelium was studied in rubbed vessels. After the endothelium was removed, the HCO 3 Ϫ -dependent reduction of Cyt c by O 2 Ϫ ⅐ was virtually eliminated, implicating endothelial NOS (eNOS) as a source of O 2 Ϫ ⅐ (Fig. 3B) . eNOS is a known source of 
O 2
Ϫ ⅐ under certain conditions associated with uncoupling of enzyme oxygenase and reductase activities. In PA segments, both Cyt c reduction and oxidation were prevented by the eNOS inhibitor N G -nitro-L-arginine methyl ester (L-NAME, 100 M), but not its inactive enantiomer N G -nitro-D-arginine methyl ester (D-NAME), further supporting eNOS as the source of O 2 Ϫ ⅐ (Fig. 4A) . Loss of oxidation after L-NAME suggests that O 2 Ϫ ⅐ originating from eNOS can also be reduced to H 2 O 2 in the PA, e.g., within endothelial cells. In rat PA segments, O 2 Ϫ ⅐ production by eNOS was due in part to L-arginine limitation because supplemental L-arginine (100 M) attenuated but did not eliminate Cyt c reduction ( Fig. 4B) (n ϭ 4, P Ͻ 0.05). Uncoupling eNOS activity by administration of the heat shock protein-90 (HSP-90) inhibitor geldanamycin (10 M) increased O 2 Ϫ ⅐ production in K-B threefold, further implicating O 2 Ϫ ⅐ production by eNOS (Fig. 4B) . In PA segments in K-H buffer, geldanamycin also increased O 2 Ϫ ⅐ release but its effect was nearly fivefold less than in K-B buffer due partly to the lack of baseline O 2 Ϫ ⅐ leak under these conditions (data not shown).
The effects of hypoxia on AE2 protein and mRNA expression were evaluated in the rat pulmonary vasculature. The mRNA was present constitutively but did not change significantly after 1, 3, or 7 days of hypoxia (data not shown). However, after 1, 3, or 7 days of hypobaric hypoxia at 17,000 ft. altitude, lung AE2 expression by Western blot analysis was strongly increased (Fig. 5A) . By immunochemical staining, AE2 was present in both PA endothelial and vascular smooth muscle cells (Fig. 5B) . Specificity was determined using immunoprecipitated AE2 protein to confirm the identity of the single 95-kDa band and peptide competition (1:10) to inhibit the signal (data not shown). We have not yet determined why the protein expression increased, whereas the mRNA did not.
Reduction of Cyt c was increased significantly in K-B buffer in PA segments of rats treated with 3 days of hypoxia compared with control vessels (Fig. 6A) . Increased Cyt c reduction corresponded to diminished NO-mediated vasodilation. In PA rings of hypoxiaexposed rats, ACh vasodilation was attenuated significantly compared with the responses of rings from control rats. To measure the vascular response to ACh, rings were preconstricted with PE (10 Ϫ6 M), and the decrease in vascular tone with ACh (10 Ϫ5 M) was expressed relative to the peak constriction with PE (10 Ϫ6 M) (% maximum constriction). Vasorelaxation to ACh was significantly less in rings from hypoxiatreated rats (41.7 Ϯ 0.04% in rings of control rats vs. 70.3 Ϯ 0.04%, in rings of hypoxia-treated rats; n ϭ 4, P Ͻ 0.05) (Fig. 6B) . In rings from hypoxia-exposed animals, treatment with SOD increased the response to ACh by twofold, similar to control rings, whereas incubation with catalase did not restore the response to ACh (Fig. 6B) . These findings indicate that extracellular O 2 Ϫ ⅐ in PAs increased following exposure to hypoxia and contributed to decreased NO-mediated vasodilation by ACh.
In rings from hypoxia-exposed rats studied at the same PO 2 as control rings, the reduction of Cyt c in K-B buffer remained HCO 3 Ϫ dependent. However, Cyt c reduction was no longer inhibited by L-NAME (Fig.  6C ). This loss of L-NAME effect indicated that the O 2 Ϫ ⅐ release was derived not from eNOS but from a different source. In addition, removal of the endothelium by rubbing the vessels no longer eliminated the ability of Ϫ ⅐ release increased in PA of hypoxia-exposed animals. A: pretreatment with 3 days of hypobaric hypoxia (3 d Hypo K-B) significantly increased Cyt c reduction in PAs from hypoxiaexposed rats compared with control animals (Control K-B) (n ϭ 4, P Ͻ 0.05). B: maximum relaxation to ACh (10 Ϫ5 M) was decreased in PA rings from hypoxia-exposed rats (Hypo). Scavenging O 2 Ϫ ⅐ with exogenous Cu,Zn SOD (Hypo ϩ SOD) (n ϭ 2) restored the ACh response, whereas catalase (Hypo ϩ cat) did not (n ϭ 2). C: HCO 3 Ϫ -dependent Cyt c reduction was no longer blocked by L-NAME (3 d Hypo L-NAME), indicating a different source of O 2 Ϫ ⅐.
the vessel to reduce Cyt c (Fig. 7A ). This indicated that vascular smooth muscle, not endothelium, was the source of O 2 Ϫ ⅐. Experiments were conducted to investigate the source of O 2 Ϫ ⅐ production in the posthypoxic vessels. Pretreatment with oxypurinol (100 M) to inhibit xanthine oxidase, 1-aminobenzatriazole (20 M) to inhibit cytochrome P-450, or rotenone (10 M) to block complex I of mitochondrial electron transport did not inhibit Cyt c reduction, excluding these enzymes as the predominant sources of extracellular O 2 Ϫ ⅐ in these pulmonary vessels (P Ͼ 0.05, n ϭ 3 for each) (Fig. 8, A-C) . In addition, Cyt c reduction was not inhibited by any of the three concentrations of diphenyleneidonium chloride (DPI, 5, 25, and 50 M), which was used to inhibit NADPH oxidase, an important vascular source of O 2 Ϫ ⅐ (Fig. 8D) . The DPI and rotenone studies were repeated after 3 days of hypoxia in rubbed PA segments to facilitate uptake of the compounds by smooth muscle cells (Fig. 7, A-C) . Neither of these inhibitors interfered with HCO 3 Ϫ -dependent Cyt c reduction in exhypoxic vessels after removal of the endothelium (P Ͼ 0.05, n ϭ 3).
DISCUSSION
This work reports a novel role for HCO 3 Ϫ -dependent release of extracellular O 2 Ϫ ⅐ in regulating NO-mediated pulmonary vascular responses in the rat. We first demonstrated that the appearance of extracellular O 2 Ϫ ⅐ in both the intact rat lung and rat PA, detected by NBT reduction and SOD-inhibitable Cyt c reduction, requires the presence of HCO 3 Ϫ . These findings are consistent with our previous reports of HCO 3 Ϫ -dependent release of O 2 Ϫ ⅐ in isolated perfused rabbit lungs and cultured human bronchial epithelial cells (HBEC) (30) (9). Diminished extracellular O 2 Ϫ ⅐ release in HCO 3 Ϫ -free buffer was not attributable to differences in buffer osmolarity or extracellular pH, which were equivalent in both buffers and stable throughout the experimental period. Decreased NBT or Cyt c reduction in HCO 3 Ϫ -free buffer was not likely due to changes in intracellular pH because pH is predominantly maintained by intracellular proteins, whose ionization should not be greatly altered by extracellular buffer substitution experiments (11) . Small changes in Na ϩ concentration in the two buffers could have a small impact in the function of other cation transport proteins but would not likely explain our results because this would not account for differences in extracellular O 2 Ϫ ⅐ release in the presence of stilbene inhibitors.
In the intact lung, the strong qualitative decrease in O 2 Ϫ ⅐ measured by NBT reduction was not attributable to the difference in buffer composition because potassium superoxide placed on the surface of the lung reduces NBT in HCO 3 Ϫ -free HEPES buffer (30) . In PA segments, the small amount of reduced Cyt c present in the preparation was instead oxidized by H 2 O 2 in HCO 3 Ϫ -free buffer because H 2 O 2 formed within cells by dismutation of O 2 Ϫ ⅐ diffuses freely across plasma membranes. Therefore, the reaction of H 2 O 2 with Cyt c outside the vessel was not eliminated by the prevention of HCO 3 Ϫ -dependent O 2 Ϫ ⅐ transport. HCO 3 Ϫ influenced the vascular response in isolated PA rings to both NO-mediated pulmonary vasodilation with ACh and acute HPV. In HCO 3 Ϫ -free conditions, vasorelaxation by ACh, which is mediated by release of endothelium-derived NO, was enhanced in accordance with increased NO bioactivity that occurs when less extracellular O 2 Ϫ ⅐ is available to react with NO. HCO 3 Ϫ -free conditions also blunted acute hypoxic vasoconstriction, which could also be mediated by increased NO bioactivity. The mechanisms of acute HPV are complex and incompletely understood, although there is substantial evidence that NO influences vascular tone in hypoxia. For example, severe hypoxia limits NOS activity (12, 20) , and NOS inhibition accentuates HPV (44) . Vasoconstriction in severe hypoxia may be further exacerbated by increased production of O 2 Ϫ ⅐ under hypoxic conditions (15) .
The decreased vascular tone in HCO 3 Ϫ -free conditions correlated with decreased extracellular O 2 Ϫ ⅐, which supports the hypothesis that HCO 3
Ϫ ⅐ generation modulates NO-mediated pulmonary vasodilation. These findings are consistent with published work on hyperoxia in which buffer substitution and AE protein inhibitors protected isolated perfused rabbit lungs against pulmonary hypertension, decreased extracellular O 2 Ϫ ⅐, and increased NO (30) . The simplest interpretation of these findings is that HCO 3 Ϫ at the cell membrane exchanges rather than chemically competes for O 2 Ϫ ⅐ with the near-diffusion limited reaction of O 2 Ϫ ⅐ with NO. Although alkalosis and acidosis are well known to affect tone in the PA, this is the first evidence that HCO 3 Ϫ directly regulates vascular tone at physiological pH and normal CO 2 tension (25, 34, 40, 46) .
A large body of observations by our group and others strongly implicates the lung AE protein in the HCO 3 Ϫ -dependent transport of O 2 Ϫ ⅐ to the extracellular compartment. The removal of HCO 3 Ϫ from buffers or media and incubations with stilbene inhibitors have been useful to block HCO 3 Ϫ -Cl Ϫ exchange activity by AE (22, 24, 30) . In this study, Cyt c reduction by the PA was decreased by substitution with HCO 3 Ϫ -free buffer and after pretreatment with the AE inhibitor SITS. This HCO 3 Ϫ requirement in the rat is consistent with our data in perfused rabbit lungs in which HCO 3 Ϫ -free buffers and the related AE inhibitor DIDS prevented both Cyt c reduction and NBT reduction (30) . Also in cultured HBEC, loss of AE2 function in HCO 3 Ϫ -free media or SITS prevented generation of extracellular O 2 Ϫ ⅐ (9). Studies in erythrocytes, the brain, and the lung have used AE inhibitors to block transport of O 2 Ϫ ⅐ across cell membranes, but these are the first studies to link AE2 and HCO 3 Ϫ -dependent vascular O 2 Ϫ ⅐ transport (10, 14, 17, 23, 30 (41, 45) ; (16, 36) . In this study, L-arginine availability played a role ex vivo in O 2 Ϫ ⅐ generation because supplementation with L-arginine partially attenuated O 2 Ϫ ⅐ release. BH 4 was not evaluated specifically, but it should be available in fresh tissue. Release of O 2 Ϫ ⅐ by eNOS also involves HSP-90, which if uncoupled from eNOS activity increases O 2 Ϫ ⅐ production by eNOS (33) . The specific HSP-90 inhibitor geldanamycin significantly increased O 2 Ϫ ⅐ release, further implicating eNOS-containing cells as the source. Geldanamycin can participate in redox reactions to generate O 2 Ϫ ⅐ independently (7), but O 2 Ϫ ⅐ release by the PA after geldanamycin was greatly attenuated in HCO 3 Ϫ -free buffer.
In this study, continuous hypoxia altered the source of O 2 Ϫ ⅐ generation in the rat PA; eNOS no longer was the primary source of extracellular O 2 Ϫ ⅐. In exhypoxic vessels, neither L-NAME nor removal of endothelium blocked Cyt c reduction, indicating that another site, presumably in the vascular smooth muscle cell, was producing the bulk of the extracellular O 2 Ϫ ⅐. However, other well-known sources of O 2 Ϫ ⅐ could not be implicated in the HCO 3 Ϫ -dependent generation of extracellular O 2 Ϫ ⅐, including the mitochondrial electron transport chain, NAD(P)H oxidase, xanthine oxidase, cyclooxygenase, or P450 enzymes. NADPH oxidase and mitochondrial electron transport have been identified as important sources of O 2 Ϫ ⅐ in some hypoxia experiments (6, 26, 43) in hypoxia was associated with a decreased vasodilator response to ACh. These measures were performed in normoxia after prolonged hypoxia and, therefore, may reflect smooth muscle alterations of hypoxia and/or responses to reoxygenation.
The increase in HCO 3 Ϫ -dependent release of O 2 Ϫ ⅐ in the PA after alveolar hypoxia suggests that hypoxia, which is associated with ROS, might increase AE2 protein expression. We found that hypoxia increases AE2 protein expression in PA smooth muscle, which suggests AE2 is important not only as previously believed to regulate intracellular pH and cell volume (24) , but to regulate O 2 Ϫ ⅐ transport in hypoxia. The increase in AE2 expression in vascular smooth muscle correlated with endothelium-independent increases in O 2 Ϫ ⅐ released (in rubbed vessels). Computer analysis of the AE2 promoter sequence indicates consensus sequences for transcription factors such as AP-1 and HSF, which may provide mechanisms for its regulation by oxygen tension (39) (Transcription Factor Search). The novel function for AE2 in the transport of O 2 Ϫ ⅐ in the rat PA and a report that NO export by red blood cells is mediated by AE1 suggests a general role for AE proteins in vasoregulation by NO and O 2 Ϫ ⅐ (32). In summary, we report a novel mechanism by which O 2 Ϫ ⅐ generated by eNOS is released from the PA endothelium in the presence of HCO 3 Ϫ to regulate pulmonary vascular tone. The O 2
Ϫ ⅐ efflux appears to be mediated by an AE2 transport mechanism. Such a transport mechanism may also facilitate O 2 Ϫ ⅐ during hypoxia from smooth muscle sources when intracellular O 2 Ϫ ⅐ production is increased. The findings also suggest a new avenue of research into O 2 Ϫ ⅐-dependent mechanisms of vasoconstriction, which may lead to novel therapies for diseases associated with alveolar hypoxia.
